Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Calcium D-saccharate is a small molecule calcium salt of D-saccharic acid (also known as D-glucaric acid) developed and manufactured by West Bengal Chemical Industries Limited (WBCIL). It is intended for oral administration and is primarily utilized as a bioavailable source of calcium and a nutraceutical ingredient. In the WBCIL pipeline, it is being developed for indications including hypertension, osteoporosis, and colon cancer. While its primary function is mineral supplementation, saccharate compounds are often investigated for their potential to inhibit beta-glucuronidase, an enzyme involved in the deconjugation of toxins and hormones, thereby potentially aiding in detoxification and cancer chemoprevention. The compound is currently in the 'Under Scale Up' phase of development at WBCIL.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on calcium D-saccharate.